ERBB2 and breast cancer: It did not show significantly lower correlation with LuminalA MET500 breast cancer samples than MDA-MB-415 (Supplementary Fig. 8b); however, compared to EFM192A, it was significantly less correlated with Her2-enriched MET500 breast cancer samples (Supplementary Fig. 8c).